title: A randomized trial of superovulation with two different doses of letrozole.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effects of either a 2.5-mg or a 5-mg daily dose of letrozole in women undergoing superovulation and intrauterine insemination (IUI).
  
  
  METHODS
  Prospective randomized trial.
  
  
  METHODS
  Academic teaching hospital.
  
  
  METHODS
  Women <40 years old, with patent fallopian tubes and infertility of >1 year in duration.
  
  
  METHODS
  Patients were randomized into either a 2.5-mg dose of letrozole (34 patients) or a 5-mg dose of letrozole (38 patients) daily for 5 days. When the leading follicle reached 18 mm in diameter, ovulation was triggered by an injection of hCG and IUI was performed 24 and 48 hours later.
  
  
  METHODS
  The number of follicles, endometrial thickness, and pregnancy rate.
  
  
  RESULTS
  Compared with those treated with 2.5 mg of letrozole, the total number of follicles was significantly higher in patients receiving 5 mg of letrozole. No difference in the endometrial thickness was found between the two groups. The pregnancy rate per cycle in patients receiving 5mg of letrozole was statistically higher than in patients receiving 2.5 mg of letrozole (26.3% vs. 5.9%, P<.05). No multiple pregnancies occurred.
  
  
  CONCLUSIONS
  Compared with the daily dose of 2.5 mg, 5 mg of letrozole is associated with more follicles and a higher pregnancy rate. It appears that 5 mg daily for 5 days is a preferable letrozole dose for superovulation.
authors.affiliation: Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada.
authors.forename: Raedah
authors.initials: R
authors.lastname: Al-Fadhli
authors.forename: Camille
authors.initials: C
authors.lastname: Sylvestre
authors.forename: William
authors.initials: W
authors.lastname: Buckett
authors.forename: Seang Lin
authors.initials: SL
authors.lastname: Tan
authors.forename: Togas
authors.initials: T
authors.lastname: Tulandi
mesh_terms: D000328:Adult; D047072:Aromatase Inhibitors / Q000008:administration & dosage*; D004717:Endometrium / Q000166:cytology / Q000187:drug effects; D005260:Female; D006801:Humans; D007315:Insemination, Artificial; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage*; D006080:Ovarian Follicle / Q000166:cytology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole